QTTB Q32 Bio Inc: רווח למניה בשנים עשר החודשים האחרונים

Precision drug logistics minimize supply disruptions, yet the rolling 12-month earnings per share trend for Q32 Bio Inc. (QTTB) on GURU.Markets reflects market volatility, where 3.33 captures the magnitude of this parameter. Scientific alliances in the fight against renal pathologies, along with robust patent protection and the complexity of navigating FDA filters, ensure stability by creating insurmountable barriers to entry for new players.

As a portfolio manager, I view this indicator as the final filter for capital efficiency. The metric is calculated by dividing total annual net income by the total number of shares, reflecting the actual income per share. By analyzing the current trailing 12-month EPS, an investor assesses the business's ability to generate cash flow. For Q32 Bio Inc. (QTTB), this figure demonstrates a transition stage from R&D expenditures to patent monetization. The high margins of antibodies should transform the price action on this chart into sustainable growth in the future.